TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25567584

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy including education, audit and feedback, organizational interventions, team-directed interventions, reminders, and patient-mediated interventions.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Number of subjects: 9
Study: 22337343

Group type: EXPERIMENTAL
Intervention: Sensory focusing
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Active distraction
Number of subjects: 123

Group type: COMPARATOR
Intervention: Undirected control
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Pre-colposcopy psychometric measures
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: State anxiety post-colposcopy
Number of subjects: 123
Study: 19771504

Group type: EXPERIMENTAL
Intervention: EDM feedback counseling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 80
Study: 18687830

Group type: EXPERIMENTAL
Intervention: Ultrasound measurements of the median nerve cross-sectional area at the tunnel inlet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ultrasound parameters
Number of subjects: 27
Study: 15755389

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of flu vaccine (FV)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of flu vaccine (FV)
Number of subjects: 59
Study: 12438002

Group type: EXPERIMENTAL
Intervention: Cytokinesis-block micronucleus (CBMN) assay in peripheral lymphocytes
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cytokinesis-block micronucleus (CBMN) assay with fluorescent in situ hybridization
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cytokinesis-block micronucleus (CBMN) assay
Number of subjects: 29
Study: 10619106

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Children with cerebral palsy
Number of subjects: 26
Study: 7795944

Group type: EXPERIMENTAL
Intervention: Matrix task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random generation of numbers (secondary task)
Number of subjects: 0
Study: 1851340

Group type: EXPERIMENTAL
Intervention: Zileuton (800 mg, single oral dose)
Number of subjects: 9
Study: 6996072

Group type: EXPERIMENTAL
Intervention: Diflunisal (0.5‐1 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (2‐4 g/day)
Number of subjects: 0
Study: 31771599

Group type: EXPERIMENTAL
Intervention: Multicomponent multidisciplinary collaborative intervention
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 503
Study: 28547861

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.4 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inorganic nitrate (12.9 mmoL)
Number of subjects: 42
Study: 26062186

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion treatment applied twice a week for 8 weeks.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Blank control group receiving health and psychological guidance only.
Number of subjects: 44
Study: 24053172

Group type: EXPERIMENTAL
Intervention: Integrated community case management of malaria and pneumonia
Number of subjects: 1276
Study: 20680890

Group type: EXPERIMENTAL
Intervention: Shape combined with size or colour in classification tasks
Number of subjects: 340

Group type: COMPARATOR
Intervention: Shape irrelevant to the task
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Simple similarity effects in clustering
Number of subjects: 340
Study: 19261602

Group type: EXPERIMENTAL
Intervention: Cavotricuspid isthmus block (CTIB) in addition to circumferential pulmonary vein ablation (CPVA)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein ablation (CPVA) alone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Overall patients after a single procedure
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Including reprocedures
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Patients with documented AF or AFL in Holter recordings at 12 months
Number of subjects: 149
Study: 17439907

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (GB), 120 mg twice a day for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 15298718

Group type: EXPERIMENTAL
Intervention: Misoprostol 5 x 200 microg (1 orally, 2 sublingually, 2 rectally)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo (similar to misoprostol)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 237
Study: 12428182

Group type: EXPERIMENTAL
Intervention: Eight-polar tactile-electrode impedance method
Number of subjects: 50
Study: 9640413

Group type: EXPERIMENTAL
Intervention: Continuous GH replacement for 3 years (Group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Short course GH replacement for 6-12 months (Group B)
Number of subjects: 15
Study: 7709995

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 2766313

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) mouthrinse used for 3 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Habitual oral hygiene
Number of subjects: 10
Study: 939970

Group type: EXPERIMENTAL
Intervention: Radiation therapy totaling 4000 to 4500 rads in 4 to 5 weeks (Group 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) 130 mg/sq m orally every 6 weeks (Group 2)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus CCNU (Group 3)
Number of subjects: 41
Study: 31960448

Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D3
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin D3
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 31559066

Group type: EXPERIMENTAL
Intervention: Health belief model (HBM) education, n=47
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional method education, n=52
Number of subjects: 99
Study: 28257318

Group type: EXPERIMENTAL
Intervention: Self-gripping polyester mesh (Progrip)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Sutured polyester mesh
Number of subjects: 331
Study: 24150125

Group type: EXPERIMENTAL
Intervention: Professional athletes
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Grade/middle school athletes
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Collegiate athletes
Number of subjects: 172

Group type: COMPARATOR
Intervention: All athletes
Number of subjects: 172
Study: 24079855

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 226

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 226
Study: 21626363

Group type: EXPERIMENTAL
Intervention: CT colonography (CTC)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Barium enema (BE)
Number of subjects: 921
Study: 18277876

Group type: EXPERIMENTAL
Intervention: Diskectomy
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 1191
Study: 16133077

Group type: EXPERIMENTAL
Intervention: 0.35% povidone-iodine solution followed by normal saline solution
Number of subjects: 244

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 244
Study: 12645704

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 180
Study: 10784629

Group type: EXPERIMENTAL
Intervention: 1p36 loss of heterozygosity (LOH)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 1p36 LOH status in single-copy MYCN cases
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 1p36 LOH in low-risk neuroblastoma patients
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 1p36 LOH in multivariate regression model
Number of subjects: 238
Study: 8867559

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus amiloride (Group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus captopril (Group II)
Number of subjects: 0
Study: 1361775

Group type: EXPERIMENTAL
Intervention: AA (1%) dialysate for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dextrose only (usual treatment) for 4 weeks
Number of subjects: 16
Study: 6365233

Group type: EXPERIMENTAL
Intervention: Hexabrix 320 (580 mOsm kg‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conray 420 (2500 mOsm kg‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conray 420
Number of subjects: 100
Study: 30032889

Group type: EXPERIMENTAL
Intervention: Mother's recorded voice (Group M, n=33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Stranger's recorded voice (Group S, n=33)
Number of subjects: 66
Study: 27356701

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to classical songs through headphones)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 73
Study: 25448628

Group type: EXPERIMENTAL
Intervention: QbOpen (clinician has immediate access to a QbTest report)
Number of subjects: 0

Group type: COMPARATOR
Intervention: QbBlind (report is withheld until the study end)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QbOpen
Number of subjects: 0

Group type: COMPARATOR
Intervention: QbBlind
Number of subjects: 0
Study: 22883540

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Business as usual (Control)
Number of subjects: 0
Study: 20030904

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (LGI) foods
Number of subjects: 38

Group type: COMPARATOR
Intervention: High glycaemic index (HGI) foods
Number of subjects: 38
Study: 18544744

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 10101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study: 16003041

Group type: EXPERIMENTAL
Intervention: Exercise capacity (W)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ST depressions during exercise test
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Left ventricular diameter (cm/m)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Left ventricular volume (mL/m)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Right ventricular diameter (cm/m)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Left atrial volume (mL/m)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Stroke volume (mL/m)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Interventricular septum thickness (mm)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Posterior wall thickness (mm)
Number of subjects: 39
Study: 12794406

Group type: EXPERIMENTAL
Intervention: Genotyping using restriction fragment length polymorphism
Number of subjects: 46
Study: 10966086

Group type: EXPERIMENTAL
Intervention: Community-based intervention programs targeting dietary behavior and adolescent substance abuse in 11 intervention communities.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control communities (matched controls for the intervention communities).
Number of subjects: 14
Study: 9207635

Group type: EXPERIMENTAL
Intervention: TIMI IIIB trial
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Cardiac catheterization and percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Proportion of unstable angina and non‐Q wave MI
Number of subjects: 1473
Study: 8398323

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant doxorubicin with marginal surgery and postoperative radiotherapy (51 Gy in 17 fractions)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Salvage treatment after local recurrence
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant doxorubicin with marginal surgery and postoperative radiotherapy
Number of subjects: 240
Study: 3962762

Group type: EXPERIMENTAL
Intervention: 5000 units calcium heparin subcutaneously 8-hourly for two weeks
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 305
Study: 31613046

Group type: EXPERIMENTAL
Intervention: Preprocedural anticoagulation (63% of patients, primarily intravenous unfractionated heparin)
Number of subjects: 10064

Group type: EXPERIMENTAL
Intervention: Preprocedural anticoagulation
Number of subjects: 10064
Study: 30214185

Group type: EXPERIMENTAL
Intervention: GFF MDI (glycopyrrolate/formoterol fumarate, 18/9.6 μg, twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GFF MDI
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 20
Study: 27619983

Group type: EXPERIMENTAL
Intervention: ipragliflozin (50-100 mg once daily)
Number of subjects: 480

Group type: COMPARATOR
Intervention: control (continuation of conventional therapy)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 480

Group type: COMPARATOR
Intervention: control
Number of subjects: 480
Study: 24862215

Group type: EXPERIMENTAL
Intervention: Rilpivirine long-acting (RPV-LA) 300 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Rilpivirine long-acting (RPV-LA) 600 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Rilpivirine long-acting (RPV-LA) 1,200 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 66
Study: 22311939

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (Low GI) diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Calorie restricted (Low Cal) diet
Number of subjects: 23
Study: 20210844

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Both genders
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Blood glucose level at randomization and updated glucose concentration during follow-up
Number of subjects: 1253
Study: 18626654

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Knot tying technique (KT)
Number of subjects: 200
Study: 16685882

Group type: EXPERIMENTAL
Intervention: Harmonic skeleton guided evaluation of stenoses in human coronary arteries
Number of subjects: 0
Study: 12628949

Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg daily)
Number of subjects: 9297

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study: 10776077

Group type: EXPERIMENTAL
Intervention: Gradient ultrafiltration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Constant ultrafiltration
Number of subjects: 20
Study: 9061125

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (400 mL daily during hospital stay and 200 mL daily for 6 months at home)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (SG-)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (usual care without supplements)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (SG+)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 46
Study: 1900008

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 6091169

Group type: EXPERIMENTAL
Intervention: Azathioprine and low-dose prednisolone
Number of subjects: 145

Group type: COMPARATOR
Intervention: Cyclosporin A
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Primary CMV infections
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Secondary CMV infections
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 145
Study: 30786835

Group type: EXPERIMENTAL
Intervention: JVS-100 8 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: JVS-100 16 mg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: All groups (JVS-100 and placebo)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 109
Study: 29966016

Group type: EXPERIMENTAL
Intervention: SRLS 100 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: SRLS 200 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: SRLS 400 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: PLGA 100 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Non-administration group
Number of subjects: 99
Study: 26949137

Group type: EXPERIMENTAL
Intervention: Fluticasone plus Salmeterol
Number of subjects: 11679

Group type: COMPARATOR
Intervention: Fluticasone alone
Number of subjects: 11679
Study: 25278810

Group type: EXPERIMENTAL
Intervention: King Vision™ video laryngoscope (KV group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional blind insertion (Blind group)
Number of subjects: 60
Study: 22507696

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study: 20586676

Group type: EXPERIMENTAL
Intervention: New adjustable length titanium ossicular prosthesis (ALTO)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (age- and pathology-matched)
Number of subjects: 14
Study: 17433902

Group type: EXPERIMENTAL
Intervention: Oral formulations of female hormone replacement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heritable and acquired risk factors for thrombosis
Number of subjects: 0
Study: 15827780

Group type: EXPERIMENTAL
Intervention: Cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (35 mg/m2) at 40-41 degrees C for 90 minutes
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Complete cytoreduction
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Minimal residual disease
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Gross macroscopic tumor left behind
Number of subjects: 117
Study: 12221381

Group type: COMPARATOR
Intervention: 20% benzocaine gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: 60% lidocaine gel
Number of subjects: 20
Study: 10547222

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 40 mg orally 15 minutes before thrombolysis, followed by 20 mg every 8 hours
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 7599825

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fatigue (without aminophylline)
Number of subjects: 0
Study: 2136870

Group type: EXPERIMENTAL
Intervention: Paroxetine (n = 27)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clomipramine (n = 17)
Number of subjects: 44
Study: 692838

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate
Number of subjects: 39
Study: 31766063

Group type: EXPERIMENTAL
Intervention: Improvement of 25(OH)D levels from <75 nmol/l to ≥75 nmol/l (median: 40.2 nmol/l to 83.2 nmol/l)
Number of subjects: 933

Group type: COMPARATOR
Intervention: Control group with consistently <75 nmol/l 25(OH)D levels
Number of subjects: 933
Study: 27714914

Group type: EXPERIMENTAL
Intervention: Telephone assessment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Face-to-face assessment
Number of subjects: 108
Study: 25909205

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 33

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 33
Study: 23392460

Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF)
Number of subjects: 700

Group type: COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)
Number of subjects: 700
Study: 21311765

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 39597

Group type: EXPERIMENTAL
Intervention: Folic acid with low prevalence of antiplatelet therapy (60% on average)
Number of subjects: 39597

Group type: EXPERIMENTAL
Intervention: Folic acid with high prevalence of antiplatelet therapy (91% on average)
Number of subjects: 39597

Group type: COMPARATOR
Intervention: MTHFR gene mutation (CT)
Number of subjects: 39597
Study: 19120433

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 29

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 29
Study: 17284097

Group type: EXPERIMENTAL
Intervention: Remifentanil (bolus of 1.0 microg/kg, continuous infusion from 0.25 to 0.05 microg/kg/min)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Alfentanil (bolus of 10 microg/kg, continuous infusion from 2.0 to 0.5 microg/kg/min)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 33
Study: 14997022

Group type: EXPERIMENTAL
Intervention: Serum zinc levels
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurements
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Comparison of lumbar BMD Z-scores in females with severe zinc deficiency
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Serum zinc levels in females with femoral BMD Z-scores < -2
Number of subjects: 131
Study: 16861150

Group type: EXPERIMENTAL
Intervention: Psychotropic analgesic nitrous oxide (PAN)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Oxygen (O2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 9862845

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 46
Study: 8572836

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 2365
Study: 1827098

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg 12-hourly for 14 days
Number of subjects: 208

Group type: COMPARATOR
Intervention: Erythromycin stearate 500 mg 6-hourly for 14 days
Number of subjects: 208